Genetic tests showed that certain patients were predisposed to brain injuries if they took the drugs. That information ...

Biogen Inc. (Nasdaq: BIIB) announced upcoming data presentations and programming at the Clinical Trials on Alzheimer’s Disease (CTAD) annual conference, taking place October 29 - November 1, in Madrid ...

a competing Alzheimer's drug. The outcome of donanemab's approval process could have substantial implications for Biogen's market position and Leqembi's uptake. In the broader neurology and ...

Eli Lilly & Co’s Alzheimer’s drug won’t be made available for patients using England’s National Health Service, after the ...

At the STAT summit, executives discuss their challenges, and hopeful signals, about breaking into markets on obesity and ...

Contract manufacturing and royalty revenues include Biogen’s 50% share of revenues (including royalties) from the collaboration with Eisai for a new Alzheimer’s drug, Leqembi and revenues from ...

Britian's National Institute for Health and Care Excellence said more evidence was needed to prove Kisunla's worth. Lilly ...

The UK's Medicines and Healthcare products Regulatory Agency approved donanemab, branded as Kisunla, making it the second ...

The UK’s healthcare spending watchdog has rejected Eli Lilly’s (LLY) Alzheimer’s drug as being too expensive despite being ...

Biogen Inc. (NASDAQ:BIIB), a leading biotechnology company specializing in neurological treatments, finds itself at a critical juncture as it navigates the launch of its highly anticipated Alzheimer's ...